Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
39 studies found for:    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Biological: 10% liquid formulation of human immunoglobulin
2 Unknown  Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention:
3 Active, not recruiting Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP);   Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Biological: IgPro20
4 Completed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Polyradiculoneuropathy
Interventions: Biological: IgPro20;   Biological: Placebo;   Biological: IgPro10
5 Completed Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Conditions: CIDP;   Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: lipoic acid
6 Active, not recruiting Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Biological: hematopoietic stem cell transplantation
7 Withdrawn High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Cyclophosphamide
8 Completed Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: NPB-01
9 Recruiting Subcutaneous Immunoglobulin for CIDP
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Immune Globulin Subcutaneous (Human)
10 Recruiting IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Intravenous Immunoglobulin
11 Completed Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Demyelinating Diseases;   Paraproteinemias
Intervention: Drug: intravenous immunoglobulin (IVIg)
12 Completed Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Drug: Fingolimod;   Drug: Placebo Comparator
13 Recruiting sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Procedure: Lumbar puncture;   Procedure: Blood sample
14 Completed Effect of Resistance and Aerobic Exercise in CIDP or MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy
Interventions: Other: Resistance training;   Other: Aerobic training
15 Completed Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: Interferon Beta-1a
16 Completed
Has Results
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;   Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
17 Recruiting Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Biological: HYQVIA
18 Recruiting Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Condition: CIDP
Intervention: Other: CIDP treated (IVIG)
19 Completed Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Drug: Subcutaneous immunoglobulin
20 Unknown  Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)
Condition: Chronic Inflammatory Demyelinating Neuropathy
Intervention: Drug: Alemtuzumab infusion

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.